EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 180 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 2.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $491,832 | -31.5% | 25,300 | 0.0% | 0.00% | – |
| Q1 2023 | $717,761 | -15.0% | 25,300 | -12.5% | 0.00% | -100.0% |
| Q4 2022 | $844,747 | +14.2% | 28,900 | +3.2% | 0.00% | 0.0% |
| Q3 2022 | $740,000 | -40.5% | 28,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,244,000 | -3.3% | 28,000 | +7.7% | 0.00% | 0.0% |
| Q1 2022 | $1,287,000 | +3.6% | 26,000 | +6.6% | 0.00% | 0.0% |
| Q4 2021 | $1,242,000 | -8.7% | 24,400 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $1,361,000 | +30.4% | 24,400 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,044,000 | -1.1% | 24,400 | -3.6% | 0.00% | 0.0% |
| Q1 2021 | $1,056,000 | -14.1% | 25,300 | -4.2% | 0.00% | 0.0% |
| Q4 2020 | $1,229,000 | +9.6% | 26,400 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $1,121,000 | -9.8% | 26,400 | +1.9% | 0.00% | 0.0% |
| Q2 2020 | $1,243,000 | +27.5% | 25,900 | +22.2% | 0.00% | 0.0% |
| Q1 2020 | $975,000 | -22.0% | 21,200 | +1.9% | 0.00% | 0.0% |
| Q4 2019 | $1,250,000 | +6.2% | 20,800 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $1,177,000 | +1.6% | 20,800 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,158,000 | +7.7% | 20,800 | -2.3% | 0.00% | 0.0% |
| Q1 2019 | $1,075,000 | +25.3% | 21,300 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $858,000 | -40.2% | 21,300 | +2.9% | 0.00% | -50.0% |
| Q3 2018 | $1,435,000 | -8.4% | 20,700 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,566,000 | +109.4% | 20,700 | +45.8% | 0.00% | +100.0% |
| Q1 2018 | $748,000 | -1.4% | 14,200 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $759,000 | -10.4% | 14,200 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $847,000 | -24.4% | 14,200 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,120,000 | -12.3% | 14,200 | -7.8% | 0.00% | -50.0% |
| Q1 2017 | $1,277,000 | +4.5% | 15,400 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $1,222,000 | +20.4% | 15,400 | +6.2% | 0.00% | 0.0% |
| Q3 2016 | $1,015,000 | +73.2% | 14,500 | -4.0% | 0.00% | +100.0% |
| Q2 2016 | $586,000 | +9.5% | 15,100 | +10.2% | 0.00% | 0.0% |
| Q1 2016 | $535,000 | -45.6% | 13,700 | +23.4% | 0.00% | -50.0% |
| Q4 2015 | $984,000 | +19.7% | 11,100 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $822,000 | +7.0% | 11,100 | +16.8% | 0.00% | 0.0% |
| Q2 2015 | $768,000 | – | 9,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |